PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy

被引:89
|
作者
Li, Qian [1 ]
Han, Jingjing [1 ]
Yang, Yonglin [2 ]
Chen, Yu [1 ]
机构
[1] Nanjing Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Nanjing, Peoples R China
[2] Nanjing Med Univ, Affiliated Taizhou Peoples Hosp, Dept Infect Dis, Taizhou, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词
PD-1; inhibitor; PD-L1; hepatocellular carcinoma; immune checkpoint; tumor immune escape; immunotherapy; REGULATORY T-CELLS; TUMOR-ASSOCIATED MACROPHAGES; TREMELIMUMAB PLUS DURVALUMAB; PD-1; BLOCKADE; OPEN-LABEL; CANCER; EXPRESSION; SORAFENIB; THERAPY; MECHANISMS;
D O I
10.3389/fimmu.2022.1070961
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Hepatocellular carcinoma (HCC) has a high prevalence and mortality rate worldwide. Sorafenib monotherapy has been the standard of first-line treatment for advanced HCC for a long time, but there are still many shortcomings. In recent years, with the deepening of research on tumor immune microenvironment, researchers have begun to explore new approaches in immunotherapy, and the introduction of immune checkpoint inhibitors has brought fundamental changes to the treatment of HCC. Programmed cell death protein 1 (PD-1) is an immune checkpoint molecule that plays an important role in down-regulating immune system function and promoting tolerance. Programmed cell death ligand 1 (PDL-1) is involved in tumor immune evasion by binding to PD-1, resulting in failure of treatment. Currently, immunotherapy targeting the PD-1/PD-L1 axis has achieved unprecedented success in HCC, but it also faces great challenges, with its low remission rate still to be solved. For most patients with HCC, the PD-1/PD-L1 pathway is not the only rate limiting factor of antitumor immunity, and blocking only the PD-1/PD-L1 axis is not enough to stimulate an effective antitumor immune response; thus, combination therapy may be a better option. In this study, changes in the immune microenvironment of HCC patients were reviewed to clarify the feasibility of anti-PD-1/PD-L1 therapy, and a series of monotherapy and combination therapy clinical trials were summarized to verify the safety and efficacy of this newly developed treatment in patients with advanced HCC. Furthermore, we focused on hyperprogressive disease and drug resistance to gain a better understanding of PD-1/PD-L1 blockade as a promising treatment.
引用
收藏
页数:17
相关论文
共 50 条
  • [21] Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors
    Zhou, Yanting
    Li, Hongyan
    FRONTIERS IN NEUROSCIENCE, 2023, 17
  • [22] Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors
    Yan, Yan
    Zhang, Li
    Zuo, Yun
    Qian, Heya
    Liu, Chang
    ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS, 2020, 68 (06)
  • [23] Cancer Immunotherapy: An Overview of Small Molecules as Inhibitors of the Immune Checkpoint PD-1/PD-L1 (2015-2021)
    Baglini, Emma
    Salerno, Silvia
    Barresi, Elisabetta
    Marzo, Tiziano
    Da Settimo, Federico
    Taliani, Sabrina
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2022, 22 (14) : 1816 - 1827
  • [24] Pyrazolones as inhibitors of immune checkpoint blocking the PD-1/PD-L1 interaction
    Le Biannic, Raphael
    Magnez, Romain
    Klupsch, Frederique
    Leleu-Chavain, Natascha
    Thiroux, Bryan
    Tardy, Morgane
    El Bouazzati, Hassiba
    Dezitter, Xavier
    Renault, Nicolas
    Vergoten, Gerard
    Bailly, Christian
    Quesnel, Bruno
    Thuru, Xavier
    Millet, Regis
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 236
  • [25] The predictive value of PD-L1 expression in patients with advanced hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors: A systematic review and meta-analysis
    Yang, Yao
    Chen, Dongbo
    Zhao, Bigeng
    Ren, Liying
    Huang, Rui
    Feng, Bo
    Chen, Hongsong
    CANCER MEDICINE, 2023, 12 (08): : 9282 - 9292
  • [26] Repurposing pentamidine for cancer immunotherapy by targeting the PD1/PD-L1 immune checkpoint
    Gu, Tingxuan
    Tian, Xueli
    Wang, Yuanyuan
    Yang, Wenqian
    Li, Wenwen
    Song, Mengqiu
    Zhao, Ran
    Wang, Mengqiao
    Gao, Quanli
    Li, Tiepeng
    Zhang, Chengjuan
    Kundu, Joydeb Kumar
    Liu, Kangdong
    Dong, Zigang
    Lee, Mee-Hyun
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [27] PD-1/PD-L1 checkpoint in hematological malignancies
    Annibali, O.
    Crescenzi, A.
    Tomarchio, V.
    Pagano, A.
    Bianchi, A.
    Grifoni, A.
    Avvisati, G.
    LEUKEMIA RESEARCH, 2018, 67 : 45 - 55
  • [28] PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations
    Jiang, Yongshuai
    Chen, Ming
    Nie, Hong
    Yuan, Yuanyang
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (05) : 1111 - 1122
  • [29] PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential
    Yang, Tianrui
    Kong, Ziren
    Ma, Wenbin
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (02) : 546 - 553
  • [30] The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy
    Jiang, Wenxiao
    Pan, Shuya
    Chen, Xin
    Wang, Zhi-wei
    Zhu, Xueqiong
    MOLECULAR CANCER, 2021, 20 (01)